More than 2,000 potential participants have been identified for screening in a Parkinson’s clinical trial, thanks to the Parkinson’s Foundation‘s PD Trial Navigator matching program. The Phase 2 trial (NCT06680830), known as NEULARK, is evaluating Neuron23‘s experimental therapy, NEU-411, in up to 150 people with early-stage,…
News
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced. The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in…
A University of Minnesota Medical School team has received a $6 million grant to design mouse models for the study of genetic variants linked to Parkinson’s disease. “These models could help us better understand how Parkinson’s disease works and support testing of potential therapies in early stages of research,”…
Biogen and Denali Therapeutics have ended their clinical development of BIIB122 for people with idiopathic Parkinson’s disease after the experimental therapy failed to slow disease progression in a Phase 2b trial. The decision follows results from the Phase 2b LUMA study (NCT05348785), which compared BIIB122 (also…
A team of researchers in Germany has developed an immuno-infrared sensor (iRS) designed to detect misfolded alpha-synuclein, a protein linked to Parkinson’s disease, in body fluids including blood and the fluid that surrounds the brain and spinal cord. The researchers say the technology could one day support earlier diagnosis,…
Herantis Pharma will use a system based on smartphone technology to measure symptom changes in a Phase 2 trial testing its Parkinson’s disease treatment HER-096. Researchers will use Indivi’s digital biomarker platform alongside conventional clinical assessments to help researchers detect early changes in motor and cognitive function in…
The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease. The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage…
A pivotal clinical trial testing the light therapy device Celeste for Parkinson’s disease has wrapped up, with the last enrolled participant completing the study’s final visit. That’s according to a company press release from device developer Photopharmics, which called the completion of the…
Topline results from a Phase 2 trial testing oral bezisterim as a first-line, stand-alone treatment for early Parkinson’s disease are expected later this year following the completion of the study’s final patient visit. The developer of the therapy, Biovie, announced that researchers…
Researchers at Texas A&M University have identified a protective brain pathway — one linked to receptors responsive to nicotine but not requiring the tobacco plant chemical itself — that may be targeted to slow the progression of Parkinson’s disease. In a mouse model of Parkinson’s, boosting the number of…
Recent Posts
- New PD Trial Navigator program flags thousands for NEULARK study
- Banning paraquat could be our Erin Brockovich moment for Parkinson’s
- Phase 2a trial of Jotrol for Parkinson’s begins enrolling patients in the U.S.
- Research team wins grant to study Parkinson’s genetics in mice
- Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s